Shaker Investments LLC OH increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 4.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,055 shares of the medical device company’s stock after buying an additional 1,545 shares during the period. DexCom accounts for approximately 2.2% of Shaker Investments LLC OH’s holdings, making the stock its 14th largest position. Shaker Investments LLC OH’s holdings in DexCom were worth $2,930,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. FMR LLC boosted its stake in DexCom by 9.1% in the first quarter. FMR LLC now owns 9,845,408 shares of the medical device company’s stock valued at $834,201,000 after buying an additional 823,406 shares in the last quarter. Vanguard Group Inc. boosted its stake in DexCom by 4.2% in the first quarter. Vanguard Group Inc. now owns 6,596,294 shares of the medical device company’s stock valued at $558,904,000 after buying an additional 263,543 shares in the last quarter. Baillie Gifford & Co. boosted its stake in DexCom by 1.4% in the first quarter. Baillie Gifford & Co. now owns 6,212,889 shares of the medical device company’s stock valued at $526,418,000 after buying an additional 84,085 shares in the last quarter. BlackRock Inc. boosted its stake in DexCom by 5,000.4% in the first quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock valued at $352,550,000 after buying an additional 4,079,283 shares in the last quarter. Finally, Janus Capital Management LLC boosted its stake in DexCom by 12.2% in the first quarter. Janus Capital Management LLC now owns 4,001,971 shares of the medical device company’s stock valued at $339,083,000 after buying an additional 436,162 shares in the last quarter.

DexCom, Inc. (NASDAQ:DXCM) opened at 71.14 on Monday. DexCom, Inc. has a one year low of $57.68 and a one year high of $96.38. The stock’s market capitalization is $6.16 billion. The firm has a 50-day moving average of $72.42 and a 200 day moving average of $75.68.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The business had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.24) earnings per share. On average, equities research analysts anticipate that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “DexCom, Inc. (DXCM) Shares Bought by Shaker Investments LLC OH” was first published by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/dexcom-inc-dxcm-shares-bought-by-shaker-investments-llc-oh.html.

A number of research analysts recently issued reports on the stock. B. Riley reissued a “buy” rating and set a $95.00 price target on shares of DexCom in a research report on Thursday, April 27th. BidaskClub cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. BMO Capital Markets reissued a “buy” rating and set a $105.00 price target on shares of DexCom in a research report on Thursday, July 13th. Oppenheimer Holdings, Inc. set a $92.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Finally, TheStreet raised shares of DexCom from a “d” rating to a “c-” rating in a research report on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and fifteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $87.00.

In related news, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $71.93, for a total value of $230,176.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $78.19, for a total transaction of $113,375.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,331 shares of company stock valued at $2,548,619. Insiders own 1.70% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.